about
Inflammation and insulin resistanceChronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistanceTranscription factor 7-like 2 polymorphism and colon cancerIL6 genotypes and colon and rectal cancerNon-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channelsSalicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitizationThe clinical applications of a systems approach.Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes.A gene expression signature for insulin resistance.Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology.Salsalate improves glycemia and inflammatory parameters in obese young adults.Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.Psychoneuroimmune implications of type 2 diabetes: reduxGetting the message across: mechanisms of physiological cross talk by adipose tissue.Variant in the 3' region of the IkappaBalpha gene associated with insulin resistance in Hispanic Americans: The IRAS Family Study.Potential role of salicylates in type 2 diabetes.Metabolic inflammation: connecting obesity and insulin resistance.Can aging be 'drugged'?The potential use of gingival crevicular blood for measuring glucose to screen for diabetes: an examination based on characteristics of the blood collection site.Drug/drug and drug/disease interactions and diabetes.Drug interactions in diabetic patients. The risk of losing glycemic control.The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes.High dose of aspirin moderates diabetes-induced changes of heart glycogen/glucose metabolism in rats.Role of innate and adaptive immunity in obesity-associated metabolic disease.
P2860
Q22241893-23694552-6EFB-482B-B173-CDE7EE302CC1Q24617743-7C346CE8-E383-4783-8BCA-8E92BE26E5E3Q24654061-B9225F94-0028-47B3-92CD-889918E3294BQ28219376-8CB1CB5B-38E1-46AD-8F8F-1F571BD8F65FQ28222323-C3913E09-8935-45F4-B177-CF96BC96C1E0Q28260504-920BC93C-826D-4A75-A0F7-2FF48630E8CFQ33242858-24C5918B-DC2C-4517-838E-30C4B543068DQ33580707-EA5C4051-334E-4FB9-8C20-F09F79F510D4Q33748389-D8E2EC41-593D-4F3B-9125-439A0DDED8D7Q33954537-9CF337B9-75AE-428E-8D39-25395AC62D62Q35580779-4EE40788-A4EE-4961-BB42-15F8C5BF365AQ37143485-8393E339-F6B6-4A34-AF41-DB3A9F2895C2Q37336959-D31B4037-72D9-4D8E-9D19-156CF77FCA9BQ37405747-CF7CA96B-A861-45CD-A730-595147CC60FCQ37712275-9C5429E0-05FE-444D-870B-C816607479ACQ37762088-0CBC980E-0FDB-4197-ADF7-BC5098479D6BQ38029782-EDA0C8F4-A2E8-4BE4-A6F4-BCD7ADD560D6Q38662550-22CCBF76-57B7-460E-9732-4A32CC3A95E1Q39887311-F9EF30CF-5BAF-4114-AE03-A41CC180B7E2Q40452090-9851ECFE-0ECA-4104-93FA-3299FFBC248FQ40882757-05716755-21F0-4FD1-89DB-6ABEEF4ACE41Q42436345-9362FC37-BFAF-4AAA-9183-52AE19E5C277Q48220808-99EF6E0B-4BCB-422B-A1D8-BA67A219E777Q49850396-FA452613-FE52-411F-9C1C-0C68C260ACE6
P2860
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Salicylates as hypoglycemic agents.
@en
type
label
Salicylates as hypoglycemic agents.
@en
prefLabel
Salicylates as hypoglycemic agents.
@en
P356
P1433
P1476
Salicylates as hypoglycemic agents.
@en
P2093
P356
10.2337/DIACARE.5.1.64
P407
P577
1982-01-01T00:00:00Z